Tag: Sciences/Humanities

Some investors say AI-themed shares have room to climb.

The blowout results and forecast indicate that demand for the company under CEO Jensen Huang isn’t short-lived, but high prices ...

The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity.

The cloud software provider has kept sales growth strong, setting up a big AI upsell.

PC recovery will only get chip maker so far as data center market pivots toward Nvidia.

Shares of Recursion Pharmaceuticals, Schrodinger and others that are implementing AI are surging.

Billionaire Masayoshi Son said he would make SoftBank “the investment company for the AI revolution” but he missed out on ...

An escalating chip war between the U.S. and China is putting chip makers in the crosshairs.

There are some clear risks, as well as opportunity, for shareholders of the Japanese tech investment company.

Large drug companies need innovation to deal with the drug-pricing law. That is a boon to smaller biotech firms.